Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.
anal cancer
biomarker
blood biomarker
cancer prevention
cancer surveillance
cervical cancer
human papillomavirus (HPV)
oropharyngeal cancer
penile cancer
screening
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
15
04
2020
revised:
06
06
2020
accepted:
14
06
2020
pubmed:
4
12
2020
medline:
15
10
2021
entrez:
3
12
2020
Statut:
ppublish
Résumé
Despite the significant societal burden of human papillomavirus (HPV)-associated cancers, clinical screening interventions for HPV-associated noncervical cancers are not available. Blood-based biomarkers may help close this gap in care. Five databases were searched, 5687 articles were identified, and 3631 unique candidate titles and abstracts were independently reviewed by 2 authors; 702 articles underwent a full-text review. Eligibility criteria included the assessment of a blood-based biomarker within a cohort or case-control study. One hundred thirty-seven studies were included. Among all biomarkers assessed, HPV-16 E seropositivity and circulating HPV DNA were most significantly correlated with HPV-associated cancers in comparison with cancer-free controls. In most scenarios, HPV-16 E6 seropositivity varied nonsignificantly according to tumor type, specimen collection timing, and anatomic site (crude odds ratio [cOR] for p16+ or HPV+ oropharyngeal cancer [OPC], 133.10; 95% confidence interval [CI], 59.40-298.21; cOR for HPV-unspecified OPC, 25.41; 95% CI, 8.71-74.06; cOR for prediagnostic HPV-unspecified OPC, 59.00; 95% CI, 15.39-226.25; cOR for HPV-unspecified cervical cancer, 12.05; 95% CI, 3.23-44.97; cOR for HPV-unspecified anal cancer, 73.60; 95% CI, 19.68-275.33; cOR for HPV-unspecified penile cancer, 16.25; 95% CI, 2.83-93.48). Circulating HPV-16 DNA was a valid biomarker for cervical cancer (cOR, 15.72; 95% CI, 3.41-72.57). In 3 cervical cancer case-control studies, cases exhibited unique microRNA expression profiles in comparison with controls. Other assessed biomarker candidates were not valid. HPV-16 E6 antibodies and circulating HPV-16 DNA are the most robustly analyzed and most promising blood-based biomarkers for HPV-associated cancers to date. Comparative validity analyses are warranted. Variations in tumor type-specific, high-risk HPV DNA prevalence according to anatomic site and world region highlight the need for biomarkers targeting more high-risk HPV types. Further investigation of blood-based microRNA expression profiling appears indicated.
Sections du résumé
BACKGROUND
Despite the significant societal burden of human papillomavirus (HPV)-associated cancers, clinical screening interventions for HPV-associated noncervical cancers are not available. Blood-based biomarkers may help close this gap in care.
METHODS
Five databases were searched, 5687 articles were identified, and 3631 unique candidate titles and abstracts were independently reviewed by 2 authors; 702 articles underwent a full-text review. Eligibility criteria included the assessment of a blood-based biomarker within a cohort or case-control study.
RESULTS
One hundred thirty-seven studies were included. Among all biomarkers assessed, HPV-16 E seropositivity and circulating HPV DNA were most significantly correlated with HPV-associated cancers in comparison with cancer-free controls. In most scenarios, HPV-16 E6 seropositivity varied nonsignificantly according to tumor type, specimen collection timing, and anatomic site (crude odds ratio [cOR] for p16+ or HPV+ oropharyngeal cancer [OPC], 133.10; 95% confidence interval [CI], 59.40-298.21; cOR for HPV-unspecified OPC, 25.41; 95% CI, 8.71-74.06; cOR for prediagnostic HPV-unspecified OPC, 59.00; 95% CI, 15.39-226.25; cOR for HPV-unspecified cervical cancer, 12.05; 95% CI, 3.23-44.97; cOR for HPV-unspecified anal cancer, 73.60; 95% CI, 19.68-275.33; cOR for HPV-unspecified penile cancer, 16.25; 95% CI, 2.83-93.48). Circulating HPV-16 DNA was a valid biomarker for cervical cancer (cOR, 15.72; 95% CI, 3.41-72.57). In 3 cervical cancer case-control studies, cases exhibited unique microRNA expression profiles in comparison with controls. Other assessed biomarker candidates were not valid.
CONCLUSIONS
HPV-16 E6 antibodies and circulating HPV-16 DNA are the most robustly analyzed and most promising blood-based biomarkers for HPV-associated cancers to date. Comparative validity analyses are warranted. Variations in tumor type-specific, high-risk HPV DNA prevalence according to anatomic site and world region highlight the need for biomarkers targeting more high-risk HPV types. Further investigation of blood-based microRNA expression profiling appears indicated.
Identifiants
pubmed: 33270909
doi: 10.1002/cncr.33221
pmc: PMC8135101
mid: NIHMS1697910
doi:
Substances chimiques
Antibodies, Viral
0
Biomarkers
0
DNA, Viral
0
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
850-864Subventions
Organisme : NCI NIH HHS
ID : R01 CA251698
Pays : United States
Informations de copyright
© 2020 American Cancer Society.
Références
J Clin Oncol. 2013 Jul 20;31(21):2708-15
pubmed: 23775966
Biomed Pharmacother. 2011 Oct;65(7):496-9
pubmed: 22004597
Cancer Res. 1988 Jun 1;48(11):3282-7
pubmed: 3365707
BMJ Open. 2012 Mar 08;2(2):e000825
pubmed: 22403344
Adv Otorhinolaryngol. 2016;77:119-24
pubmed: 27116026
Int J Cancer. 2014 Jul 15;135(2):440-52
pubmed: 24338606
Int J Cancer. 2007 Feb 15;120(4):825-32
pubmed: 17131312
Gynecol Oncol. 1996 Nov;63(2):200-3
pubmed: 8910627
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):718-723
pubmed: 31437143
Gynecol Oncol. 2002 Aug;86(2):157-62
pubmed: 12144822
Int J Mol Sci. 2017 Dec 28;19(1):
pubmed: 29283429
Int J Mol Med. 2013 Sep;32(3):557-67
pubmed: 23799609
Oral Oncol. 2015 Jul;51(7):662-7
pubmed: 25957822
Int J Epidemiol. 2011 Apr;40(2):489-502
pubmed: 21224273
Lancet Oncol. 2016 Aug;17(8):1137-1146
pubmed: 27402147
J Clin Microbiol. 1998 Feb;36(2):475-80
pubmed: 9466762
Lancet Oncol. 2015 Jul;16(7):804-15
pubmed: 26088272
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):903-10
pubmed: 15361202
Oncotarget. 2017 Feb 21;8(8):13048-13058
pubmed: 28055956
J Mol Diagn. 2013 Nov;15(6):827-34
pubmed: 23988620
Lancet. 1993 May 1;341(8853):1116-8
pubmed: 8097804
Am J Pathol. 2015 Mar;185(3):679-92
pubmed: 25572154
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376197
J Hosp Med. 2013 Feb;8(2):91-5
pubmed: 23169580
Gynecol Oncol. 2010 Mar;116(3):447-51
pubmed: 19922992
Expert Rev Mol Diagn. 2014 Nov;14(8):1033-40
pubmed: 25222489
Oral Oncol. 2015 Aug;51(8):751-8
pubmed: 26094591
Int J Cancer. 2009 May 15;124(10):2375-83
pubmed: 19189402
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
J Natl Cancer Inst. 2012 Jan 18;104(2):147-58
pubmed: 22228147
PLoS One. 2012;7(9):e45246
pubmed: 23028877
Mol Med Rep. 2008 Mar-Apr;1(2):231-7
pubmed: 21479402
Hum Immunol. 1993 Jul;37(3):157-64
pubmed: 8244779
JAMA. 2018 Aug 21;320(7):687-705
pubmed: 30140883
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
J Med Virol. 2009 May;81(5):878-87
pubmed: 19319944
Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):3-6
pubmed: 11815394
N Engl J Med. 1997 Feb 27;336(9):633-40
pubmed: 9032050
Clin Cancer Res. 2019 Apr 1;25(7):2109-2115
pubmed: 30504426
Cancer Immunol Immunother. 1997 Jun;44(4):211-5
pubmed: 9222279
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
Clin Cancer Res. 2017 Jun 1;23(11):2723-2729
pubmed: 27872102
J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83
pubmed: 14652239
Am J Pathol. 2002 Jan;160(1):151-64
pubmed: 11786409
Am J Clin Nutr. 2006 Apr;83(4):895-904
pubmed: 16600944
Int J Gynecol Cancer. 2009 Oct;19(7):1269-75
pubmed: 19820390
Int J Cancer. 2014 Oct 1;135(7):1653-61
pubmed: 24615247
Mol Cell Biol. 1999 Feb;19(2):1092-100
pubmed: 9891044
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e351-8
pubmed: 21985946
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
J Cancer Res Clin Oncol. 2012 Apr;138(4):671-4
pubmed: 22237456
J Clin Oncol. 2007 Oct 10;25(29):4550-6
pubmed: 17925550
Int J Cancer. 2017 May 1;140(9):1968-1975
pubmed: 28108990
Oral Oncol. 2017 Oct;73:132-137
pubmed: 28939065
N Engl J Med. 2005 Nov 17;353(20):2158-68
pubmed: 16291985
Int J Epidemiol. 2016 Jun;45(3):752-61
pubmed: 27197530
Nutr Cancer. 2014;66(5):818-24
pubmed: 24848140
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
PLoS One. 2017 Feb 2;12(2):e0167969
pubmed: 28151938
Hum Immunol. 2003 May;64(5):538-42
pubmed: 12691704
Cancer Causes Control. 2010 Nov;21(11):1919-30
pubmed: 20820900
Int J Gynecol Cancer. 2002 Nov-Dec;12(6):741-4
pubmed: 12445252
Lancet. 2017 Nov 11;390(10108):2143-2159
pubmed: 28886907
Cell Biosci. 2016 Jan 26;6:6
pubmed: 26819702
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
Biomedica. 2006 Jun;26(2):258-68
pubmed: 16925098
J Natl Cancer Inst. 2013 Apr 17;105(8):536-45
pubmed: 23503618
J Nutr. 2001 Jul;131(7):2040-8
pubmed: 11435527
Cancer Cell Int. 2014 Aug 22;14:81
pubmed: 25788864
Int J Cancer. 2014 Nov 15;135(10):2453-61
pubmed: 24729277
Cancer Prev Res (Phila). 2019 Oct;12(10):689-700
pubmed: 31420362
J Natl Cancer Inst. 2013 Jun 19;105(12):849-59
pubmed: 23704278
Mol Med Rep. 2015 Feb;11(2):766-74
pubmed: 25384883
Anat Embryol (Berl). 2001 Nov;204(5):367-73
pubmed: 11789984
Vaccine. 2012 Sep 14;30(42):6016-9
pubmed: 22867718
PLoS One. 2017 Sep 14;12(9):e0184094
pubmed: 28910345
Semin Cancer Biol. 1999 Dec;9(6):423-30
pubmed: 10712889
Clin Otolaryngol. 2018 Oct;43(5):1242-1249
pubmed: 29763978
J Clin Oncol. 2014 Mar 10;32(8):768-73
pubmed: 24419137
Asian Pac J Cancer Prev. 2014;15(21):9313-7
pubmed: 25422218
Am J Obstet Gynecol. 2003 Jan;188(1):49-55
pubmed: 12548195
Pathol Int. 2014 Oct;64(10):499-507
pubmed: 25236707
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3713-8
pubmed: 21300873
Oncol Lett. 2018 May;15(5):7163-7167
pubmed: 29725439
Asian Pac J Cancer Prev. 2012;13(12):6475-9
pubmed: 23464477
Int J Gynecol Cancer. 2007 Jul-Aug;17(4):879-85
pubmed: 17343606
Clin Cancer Res. 2017 Nov 15;23(22):6856-6862
pubmed: 28899967
JAMA. 2018 Aug 21;320(7):706-714
pubmed: 30140882
Ann Oncol. 2019 Aug 1;30(8):1335-1343
pubmed: 31185496
J Clin Oncol. 2017 Dec 10;35(35):3964-3977
pubmed: 29068783
JAMA. 2009 Nov 18;302(19):2119-26
pubmed: 19920236
Head Neck. 2016 Nov;38(11):1634-1642
pubmed: 27097597
Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):683-9
pubmed: 25623733
Jpn J Clin Oncol. 2010 May;40(5):420-4
pubmed: 20133337
J Clin Oncol. 2020 Apr 1;38(10):1050-1058
pubmed: 32017652
Health Technol Assess. 2014 Apr;18(23):1-196
pubmed: 24762804
Sci Transl Med. 2015 Jun 24;7(293):293ra104
pubmed: 26109104
Cancer. 2017 Dec 15;123(24):4886-4894
pubmed: 28898394
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Int J Gynecol Cancer. 2009 Aug;19(6):1099-106
pubmed: 19820376
Cancer Causes Control. 2011 Jan;22(1):63-72
pubmed: 21052817
Clin Epigenetics. 2018 Jan 23;10:11
pubmed: 29410711
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724-728
pubmed: 31437140
Oncotarget. 2017 Jun 27;8(26):43571-43578
pubmed: 28388588
JAMA. 2014 Jan 22-29;311(4):392-404
pubmed: 24449318
Biochem Biophys Res Commun. 2005 Aug 26;334(2):588-92
pubmed: 16009345
Int J Gynaecol Obstet. 2007 Feb;96(2):112-6
pubmed: 17250836
J Gynecol Oncol. 2010 Sep;21(3):174-80
pubmed: 20922140
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
Oncotarget. 2017 Jul 4;8(27):44893-44909
pubmed: 28415652
Int J Cancer. 1993 Feb 1;53(3):377-81
pubmed: 8381393
Immunogenetics. 2014 Dec;66(12):683-91
pubmed: 25267060
Ann Intern Med. 2011 Nov 15;155(10):698-705, W216
pubmed: 22006929
Int J Cancer. 2020 Aug 15;147(4):1222-1227
pubmed: 31756275
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690